Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Survodutide

SYNCHRONIZE-1

Boehringer Ingelheim · Phase 3 · Completed · Enrollment 726

NCT06066515

ArmPopulationDoseWeeksEstimandWeight change
Survodutide 3.6 mgObesity + T2D3.6 mg76ITT-12.2% at week 76
Survodutide 6.0 mgObesity + T2D6.0 mg76ITT-13% at week 76
PlaceboObesity + T2Dn/r76ITT-5.4% at week 76